Treatment of Relapsed or Refractory AML with Intermediate-dose Arabinosylcytosine (Ara-C): Confirmation of the Importance of Ara-C Triphosphate Formation in Mediating Response to Ara-C-Reference-Cited by-同舟云学术

Treatment of Relapsed or Refractory AML with Intermediate-dose Arabinosylcytosine (Ara-C): Confirmation of the Importance of Ara-C Triphosphate Formation in Mediating Response to Ara-C

Published:1993-01 Issue:sup1 Volume:10 Page:115-121
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Estey Elihu H.,Plunkett William,Kantarjian Hagop,Rios Mary Beth,Keating Michael J.

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428199309149123

Reference18 articles.

1. Arabinosyl cytosine: a 20-year update.

2. Cytarabine for Acute Leukemia in Adults

3. High dose cytosine arabinoside (HDARAC) in refractory acute leukemia

4. High-dose cytosine arabinoside therapy for refractory leukemia

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials;Annals of Hematology;2021-07-07

2. Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review;Annals of Hematology;2018-04-21

3. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study;The Lancet Oncology;2015-09

4. High-dose cytarabine induction is well tolerated and active in patients with de novo acute myeloid leukemia older than 60 years;Cancer;2011-06-29

5. The Molecular Targets of Antitumor 2-deoxycytidine Analogues;Current Drug Targets;2003-05-01